← All trials
NCT04376554
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 10, 2020
- Primary completion
- Sep 15, 2021
- Completion date
- Sep 15, 2021
- First posted
- May 6, 2020
- Last posted
- May 20, 2020
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Spero TherapeuticsLead sponsor
- Karolinska InstituteOverall official - principal investigator
- IQVIACollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.